WKY |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 5 |
260.0 |
g |
7.0 |
15.65 |
body weighing method |
0.0 |
|
0 |
|
103476 |
2826 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
244.0 |
g |
8.0 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
100427 |
2479 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
317.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
|
0 |
|
100430 |
2479 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
233.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
unx |
28 |
days |
99938 |
2378 |
WKY |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
male |
360 days
| 4 |
318.0 |
g |
6.65 |
13.3 |
body weighing method |
0 |
|
0 |
|
12588 |
268 |
WKY |
body weight |
left anterior descending coronary artery occlusion then vehicle control condition |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
30 |
225.0 |
g |
1.8 |
9.86 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
100269 |
2460 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
16 |
599.0 |
g |
35.0 |
140.0 |
body weighing method |
0.0 |
lad occlusion |
210 |
days |
100274 |
2460 |
WKY |
body weight |
in utero condition (30 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
not specified |
1 days
| 36 |
4.91 |
g |
0.15 |
0.9 |
body weighing method |
0.0 |
|
0 |
|
99074 |
2218 |
WKY |
body weight |
control condition |
Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. |
body mass |
male |
245 days
| 7 |
373.6 |
g |
11.11 |
29.4 |
body weighing method |
0.0 |
|
0 |
|
99849 |
2338 |
WKY |
body weight |
streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
286.6 |
g |
21.95 |
69.41 |
body weighing method |
0.0 |
|
0 |
|
99112 |
2219 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 7 |
245.0 |
g |
9.0 |
23.81 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
100428 |
2479 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 17 |
256.0 |
g |
5.0 |
20.62 |
body weighing method |
0.0 |
unx |
150 |
days |
107446 |
2378 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 11 |
319.0 |
g |
5.0 |
16.58 |
body weighing method |
0.0 |
|
0 |
|
100394 |
2479 |
WKY |
body weight |
controlled in utero environment (100 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
male |
112 days
| 17 |
454.0 |
g |
8.0 |
32.98 |
body weighing method |
0.0 |
|
0 |
|
99075 |
2218 |
WKY |
body weight |
sham surgical control condition (for 224 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
5 |
562.0 |
g |
22.0 |
49.19 |
body weighing method |
0.0 |
lad occlusion sham |
210 |
days |
100273 |
2460 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 5 |
245.0 |
g |
12.0 |
26.83 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
100429 |
2479 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
412.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
100433 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
395.0 |
g |
7.0 |
21.0 |
body weighing method |
0.0 |
PA IV 50mg/kg |
490 |
days |
100435 |
2479 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 7 |
268.0 |
g |
13.0 |
34.39 |
body weighing method |
0.0 |
unx |
28 |
days |
99935 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
215.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
unx |
28 |
days |
99936 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 16 |
261.0 |
g |
7.0 |
28.0 |
body weighing method |
0.0 |
unx |
150 |
days |
107448 |
2378 |
WKY |
body weight |
in utero condition (30 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
male |
112 days
| 18 |
436.0 |
g |
11.0 |
46.67 |
body weighing method |
0.0 |
|
0 |
|
99076 |
2218 |
WKY |
body weight |
sham surgical control condition (for 196 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
12 |
566.0 |
g |
17.0 |
58.89 |
body weighing method |
0.0 |
lad occlusion sham |
196 |
days |
100270 |
2460 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
30 |
617.0 |
g |
52.0 |
284.82 |
body weighing method |
0.0 |
lad occlusion |
196 |
days |
100272 |
2460 |
WKY |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
female |
360 days
| 4 |
200.8 |
g |
3.45 |
6.9 |
body weighing method |
0 |
|
0 |
|
12589 |
268 |
WKY |
body weight |
left anterior descending coronary artery occlusion then furosemide |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
20 |
225.0 |
g |
3.0 |
13.42 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
100268 |
2460 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
20 |
583.0 |
g |
56.0 |
250.44 |
body weighing method |
0.0 |
lad occlusion |
196 |
days |
100271 |
2460 |
WKY |
body weight |
vehicle control condition (1 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
450.39 |
g |
9.36 |
29.6 |
body weighing method |
0.0 |
|
0 |
|
99107 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
261.43 |
g |
21.34 |
67.48 |
body weighing method |
0.0 |
|
0 |
|
99109 |
2219 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 10 |
241.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
100393 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
305.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
100432 |
2479 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
418.0 |
g |
15.0 |
42.43 |
body weighing method |
0.0 |
PA IV 50mg/kg |
490 |
days |
100434 |
2479 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 10 |
241.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
100391 |
2479 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
236.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
unx |
28 |
days |
99937 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 16 |
267.0 |
g |
9.0 |
36.0 |
body weighing method |
0.0 |
unx |
150 |
days |
107449 |
2378 |
WKY |
body weight |
controlled in utero environment (100 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
not specified |
1 days
| 26 |
6.64 |
g |
0.14 |
0.71 |
body weighing method |
0.0 |
|
0 |
|
99073 |
2218 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 12 |
323.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
100395 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 12 |
312.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
100396 |
2479 |
WKY |
body weight |
streptozotocin (60 mg/kg) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
259.65 |
g |
18.96 |
59.96 |
body weighing method |
0.0 |
|
0 |
|
99108 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
295.56 |
g |
21.89 |
69.22 |
body weighing method |
0.0 |
|
0 |
|
99110 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
287.24 |
g |
20.18 |
63.81 |
body weighing method |
0.0 |
|
0 |
|
99111 |
2219 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 11 |
249.0 |
g |
11.0 |
36.48 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
100392 |
2479 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
297.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
100431 |
2479 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 6 |
229.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
unx |
28 |
days |
99939 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 17 |
274.0 |
g |
6.0 |
24.74 |
body weighing method |
0.0 |
unx |
150 |
days |
107447 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 11 |
408.0 |
g |
10.0 |
33.17 |
body weighing method |
0.0 |
unx |
150 |
days |
107445 |
2378 |
WKY |
body weight |
sham surgical control condition |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
12 |
223.0 |
g |
1.4 |
4.85 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
100267 |
2460 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
32 |
574.0 |
g |
38.0 |
214.96 |
body weighing method |
0.0 |
lad occlusion |
210 |
days |
100275 |
2460 |